| 25A901 |
Eli Lilly and Company v. United States, et al., ex. rel., Ronald J. Streck |
Seventh Circuit |
2026-02-09 |
Application |
average-manufacturer-price false-claims-act medicaid-rebate pharmaceutical-regulation qui-tam statutory-interpretation |
Question not identified.
The petition text provided is an "Application for an Extension of Time" to file a petition for certiorari, not a petition fo… |
| 23-788 |
Hope Medical Enterprises, Inc., dba Hope Pharmaceuticals v. Fagron Compounding Services, LLC, et al. |
Ninth Circuit |
2024-01-22 |
Denied |
circuit-split drug-regulation federal-law federal-preemption food-and-drug-administration preemption state-law state-rights statutory-interpretation |
Whether the FDCA preempts state laws prohibiting the in-state sale of unapproved drugs whose sale is also prohibited as a matter of federal law by the… |
| 23A530 |
Hope Medical Enterprises, Inc. v. Fagron Compounding Services, LLC, et al. |
Ninth Circuit |
2023-12-12 |
Presumed Complete |
drug-approval enforcement fdca preemption private-litigation state-law |
Whether the Food, Drug, and Cosmetic Act's enforcement provision preempts state-law claims that mirror federal drug approval requirements |
| 19-869 |
Nicole Weber v. Allergan, Inc. |
Ninth Circuit |
2020-01-13 |
Denied |
class-iii-device class-iii-medical-device current-good-manufacturing-practices fda-preemption fda-premarket-approval manufacturing-defect medical-device product-liability res-ipsa-loquitur |
Can a plaintiff use the res ipsa loquitur doctrine as evidence that a Class III product had a manufacturing defect? |
| 18-1289 |
Allergan, Inc., et al. v. Teva Pharmaceuticals USA, Inc., et al. |
Federal Circuit |
2019-04-10 |
Denied |
blocking-patent blocking-patent-doctrine commercial-success graham-v-john-deere long-felt-need objective-indicia objective-indicia-of-non-obviousness obviousness patent-law patent-law-doctrine-of-obviousness prior-art |
Whether the Federal Circuit erred in holding that objective indicia of non-obviousness may be partially or entirely discounted where the development o… |
| 18A448 |
United States, ex rel. John A. Wood v. Allergan, Inc. |
Second Circuit |
2018-10-29 |
Presumed Complete |
None |
|